Valuation: Novogenia AG

Market Cap 78M 87.09M 71.75M 65.01M 122M 8.27B 124M 856M 343M 4.35B 327M 320M 13.72B P/E 2025
155x
P/E 2026 * -20.3x
Enterprise Value 21.9M 24.45M 20.14M 18.25M 34.12M 2.32B 34.76M 240M 96.43M 1.22B 91.77M 89.82M 3.85B EV / Sales 2025
0.85x
EV / Sales 2026 * 1.18x
Free-Float
42.5%
Yield 2025 *
6.23%
Yield 2026 * 6.62%
1 day+1.60%
1 week-1.55%
Current month-11.81%
1 month-1.55%
3 months+6.72%
6 months-9.93%
Current year-18.06%
1 week 6.2
Extreme 6.2
6.85
1 month 6.2
Extreme 6.2
6.85
Current year 5.7
Extreme 5.7
11.8
1 year 5.7
Extreme 5.7
11.8
3 years 5.05
Extreme 5.05
11.8
5 years 1.75
Extreme 1.75
12.5
10 years 1.75
Extreme 1.75
12.5
Manager TitleAgeSince
Chief Executive Officer 43 2021-03-14
Director of Finance/CFO - -
Chief Investment Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member - -
Chairman 63 2021-06-22
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%-1.55%-16.99%-28.25% 87.08M
-0.62%-1.87%+46.31%+56.99% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.44%+14.89%+47.15% 32.25B
+0.89%+20.55%-42.03%+373.03% 24.37B
Average +0.46%+5.53%+41.37%+182.87% 39.36B
Weighted average by Cap. +0.16%+4.83%+48.29%+185.42%

Financials

2025 2026 *
Net sales 56M 62.53M 51.52M 46.68M 87.25M 5.94B 88.89M 614M 247M 3.12B 235M 230M 9.85B 56.2M 62.76M 51.7M 46.84M 87.56M 5.96B 89.2M 617M 247M 3.13B 236M 231M 9.89B
Net income 3.3M 3.68M 3.04M 2.75M 5.14M 350M 5.24M 36.2M 14.53M 184M 13.83M 13.53M 580M -3.81M -4.25M -3.5M -3.18M -5.94M -404M -6.05M -41.79M -16.78M -212M -15.97M -15.63M -670M
Net Debt -56.1M -62.64M -51.6M -46.76M -87.4M -5.95B -89.04M -615M -247M -3.13B -235M -230M -9.87B -11.6M -12.95M -10.67M -9.67M -18.07M -1.23B -18.41M -127M -51.08M -647M -48.61M -47.57M -2.04B
Projected Income Statement - Annual - Novogenia AG
Logo Novogenia AG
Novogenia AG, formerly Darwin AG, is a Germany-based company, which operates as a biotechnology company. The Company is engaged in production and distribution of personalized dietary supplements and cosmetics. It offers Deoxyribonucleic Acid (DNA), genetic and blood analyses in the lifestyle segment. In addition, test results are primarily used to produce dietary supplements and cosmetics. The Company is active in Pharmaceutical and medical device trading segment as well. It uses artificial intelligence (AI) to create personalized solutions from scientific laboratory analysis data (personalized infusion therapies and In Vitro Fertilization (IVF)/reproductive genetics).
Employees
204
Date Price Change Volume
26-10-28 €6.500 +0.78% 715
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.500EUR
Average target price
17.00EUR
Spread / Average Target
+161.54%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Novogenia AG